



Spinraza® (nusinersen) J3490

When requesting Spinraza® (nusinersen), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

Spinraza is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Approved Off-label Compendial use(s)

None

Coverage Guidelines

For Spinal muscular atrophy (SMA), an individual must meet all of the following criteria:

- The diagnosis has been confirmed by genetic testing showing either homozygous mutation or deletion of the *SMN1* gene on chromosome 5q OR compound heterozygous mutation of the *SMN1* gene on chromosome 5q
- Has SMA type I or II
- For an initial authorization request, an individual has obtained baseline motor milestones using the appropriate exam(s) based on individual's age and motor ability
- For a re-authorization request, an individual is responding to Spinraza therapy (e.g., improvement in motor milestones, maintenance of motor milestones, achievement of new motor milestones)

Approval duration (initial and renewal): 12 months

References

1. Spinraza [prescribing information]. Cambridge, MA; Biogen Inc. May 2017. Available at: https://www.spinraza.com/content/dam/commercial/specialty/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf. Accessed on October 2, 2017.
2. Arnold WD, Kassam D, Kissel JT. Spinal Muscular Atrophy: Diagnosis and Management in a New Therapeutic Era. *Muscle Nerve* 2015;51(2):157-167.
3. Finkel RS, Chiriboga CA, Vajsaar J, et al. Treatment of Infantile-onset spinal muscular atrophy with nusinersen: a phase2, open-label, dose-escalation study. *Lancet* 2016;388(10063):3017-3026.

*CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2016 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.